Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Quiver Bioscience is developing a small molecule inhibitor of the Nav1.8 voltage-gated sodium channel for the treatment of chronic pain disorders. Nav1.8, encoded by the SCN10A gene, is predominantly expressed in peripheral nociceptive neurons and is a validated target for pain management due to its role in action potential firing in sensory fibers. By selectively blocking Nav1.8, this therapeutic candidate aims to provide potent analgesia while avoiding the side effects associated with non-selective sodium channel inhibitors. The program is currently in preclinical development, with potential applications in conditions such as small fiber neuropathy, lumbosacral radiculopathy, and cancer-related pain.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Nav1.8 small molecule.